Hologic Dirección

Dirección controles de criterios 4/4

El CEO de Hologic's es Steve MacMillan , nombrado en Dec 2013, tiene una permanencia de 10.33 años. compensación anual total es $15.56M, compuesta por 7.6% salario y 92.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.49% de las acciones de la empresa, por valor de $87.44M. La antigüedad media del equipo directivo y de la junta directiva es de 3.2 años y 7.3 años, respectivamente.

Información clave

Steve MacMillan

Chief Executive Officer (CEO)

US$15.6m

Compensación total

Porcentaje del salario del CEO	7.6%
Permanencia del CEO	10.3yrs
Participación del CEO	1.0%
Permanencia media de la dirección	3.2yrs
Promedio de permanencia en la Junta Directiva	7.3yrs

Actualizaciones recientes de la dirección

Recent updates

Slowing Rates Of Return At Hologic (NASDAQ:HOLX) Leave Little Room For Excitement

Sep 28

Hologic, Inc.'s (NASDAQ:HOLX) Intrinsic Value Is Potentially 35% Above Its Share Price

Aug 29

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Jul 31

Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching

Jul 18

Return Trends At Hologic (NASDAQ:HOLX) Aren't Appealing

Jun 21

Calculating The Fair Value Of Hologic, Inc. (NASDAQ:HOLX)

May 22

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Apr 25

What Does Hologic, Inc.'s (NASDAQ:HOLX) Share Price Indicate?

Apr 10

Hologic's (NASDAQ:HOLX) Returns On Capital Are Heading Higher

Mar 13

Calculating The Fair Value Of Hologic, Inc. (NASDAQ:HOLX)

Feb 14

Hologic (NASDAQ:HOLX) Seems To Use Debt Quite Sensibly

Jan 18

Is Now The Time To Look At Buying Hologic, Inc. (NASDAQ:HOLX)?

Jan 03

Shareholders Would Enjoy A Repeat Of Hologic's (NASDAQ:HOLX) Recent Growth In Returns

Dec 02

Hologic (NASDAQ:HOLX) Seems To Use Debt Quite Sensibly

Oct 12

Is Hologic, Inc. (NASDAQ:HOLX) Potentially Undervalued?

Sep 27

Hologic announces $1B share buyback program

Sep 26

We Like Hologic's (NASDAQ:HOLX) Returns And Here's How They're Trending

Aug 27

Hologic cut to Neutral at BTIG on macro concerns

Jul 18

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Jul 11

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Steve MacMillan en comparación con los beneficios de Hologic?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 30 2023	n/a	n/a	US$515m
Sep 30 2023	US$16m	US$1m	US$456m
Jul 01 2023	n/a	n/a	US$484m
Apr 01 2023	n/a	n/a	US$753m
Dec 31 2022	n/a	n/a	US$990m
Sep 24 2022	US$14m	US$1m	US$1b
Jun 25 2022	n/a	n/a	US$2b
Mar 26 2022	n/a	n/a	US$2b
Dec 25 2021	n/a	n/a	US$2b
Sep 25 2021	US$15m	US$1m	US$2b
Jun 26 2021	n/a	n/a	US$2b
Mar 27 2021	n/a	n/a	US$2b
Dec 26 2020	n/a	n/a	US$1b
Sep 26 2020	US$14m	US$1m	US$1b
Jun 27 2020	n/a	n/a	US$497m
Mar 28 2020	n/a	n/a	US$453m
Dec 28 2019	n/a	n/a	US$84m
Sep 28 2019	US$12m	US$1m	-US$204m
Jun 29 2019	n/a	n/a	-US$30m
Mar 30 2019	n/a	n/a	-US$11m
Dec 29 2018	n/a	n/a	-US$419m
Sep 29 2018	US$42m	US$1m	-US$111m
Jun 30 2018	n/a	n/a	-US$79m
Mar 31 2018	n/a	n/a	-US$132m
Dec 30 2017	n/a	n/a	US$1b
Sep 30 2017	US$11m	US$1m	US$756m

Compensación vs. Mercado: La compensación total ($USD15.56M) de Steve está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD13.51M).

Compensación vs. Ingresos: La compensación de Steve ha sido consistente con los resultados de la empresa en el último año.

CEO

Steve MacMillan (59 yo)

10.3yrs

Permanencia

US$15,555,032

Compensación

Mr. Stephen P. MacMillan, also known as Steve, serves as an Independent Chairman of the Board at Illumina, Inc. from June 02, 2023. He has been the Chairman of the Board at Hologic Inc. since June 17, 2015...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Stephen MacMillan	Chairman	10.3yrs	US$15.56m	0.98% $ 175.1m
Karleen Oberton	Chief Financial Officer	5.7yrs	US$3.93m	0.044% $ 7.9m
Essex Mitchell	Chief Operating Officer	less than a year	US$2.17m	0.00018% $ 32.1k
John Griffin	General Counsel	9.2yrs	US$3.34m	0.045% $ 8.1m
Jan Verstreken	Group President of International	no data	US$3.52m	0.031% $ 5.5m
Paul Malenchini	Chief Information Officer	2.8yrs	sin datos	sin datos
Ryan Simon	Vice President of Investor Relations	no data	sin datos	sin datos
Peter Dunne	Senior Vice President of Human Resources	less than a year	sin datos	0.0040% $ 715.2k
Monica Berthelot	VP & Chief of Staff	10.3yrs	sin datos	sin datos
Erik Anderson	Division President of Breast & Skeletal Health Solutions	3.7yrs	sin datos	0.0070% $ 1.3m
Jennifer Schneiders	President of Diagnostics Solutions	less than a year	sin datos	0.0027% $ 481.5k
Scott Christensen	Senior Vice President of Global Supply Chain	less than a year	sin datos	sin datos

3.2yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de HOLX se considera experimentado (3.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Stephen MacMillan	Chairman	10.3yrs	US$15.56m	0.98% $ 175.1m
Scott Garrett	Independent Director	10.9yrs	US$339.96k	0.018% $ 3.2m
Sally Crawford	Independent Director	16.5yrs	US$374.96k	0.056% $ 10.0m
Stacey Stewart	Independent Director	1.3yrs	US$338.44k	0.000070% $ 12.5k
Ludwig Hantson	Independent Director	5.4yrs	US$319.96k	0.0025% $ 442.3k
Charles Dockendorff	Independent Director	6.9yrs	US$344.96k	0.0066% $ 1.2m
Christiana Stamoulis	Independent Director	12.4yrs	US$319.96k	0.019% $ 3.3m
Amy Wendell	Lead Independent Director	7.3yrs	US$319.96k	0.0075% $ 1.3m
Nanaz Mohtashami	Independent Director	less than a year	US$128.96k	0.00032% $ 57.1k

7.3yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: La junta directiva de HOLX se considera experimentada (7.3 años de antigüedad promedio).

Hologic Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Independent Director notifies of intention to sell stock

Hologic, Inc., Annual General Meeting, Mar 07, 2024

Namal Nawana Announces Not to Stand for Re-Election to the Board of Hologic, Inc

Independent Director notifies of intention to sell stock

Hologic, Inc. Promotes Essex D. Mitchell to Chief Operating Officer

Chairman exercised options and sold US$2.1m worth of stock

Recent updates

Hologic, Inc. (NasdaqGS:HOLX) signed a definitive agreement to acquire Endomagnetics Ltd. for approximately $310 million.

Getting In Cheap On Hologic, Inc. (NASDAQ:HOLX) Might Be Difficult

Now 20% undervalued

Calculating The Intrinsic Value Of Hologic, Inc. (NASDAQ:HOLX)

Hologic, Inc. to Report Q2, 2024 Results on May 02, 2024

Hologic (NASDAQ:HOLX) Has A Pretty Healthy Balance Sheet

Independent Director notifies of intention to sell stock

Now 20% undervalued

Hologic, Inc. and Biotheranostics, Inc. Announces Newly Published Study Results Reveal That Use of the Breast Cancer Index®? Test

Now 20% undervalued

Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching

Hologic: Prospects For Growth As Headwinds Disappear

We Think You Can Look Beyond Hologic's (NASDAQ:HOLX) Lackluster Earnings

Hologic, Inc. Just Beat EPS By 32%: Here's What Analysts Think Will Happen Next

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2024

We Like These Underlying Return On Capital Trends At Hologic (NASDAQ:HOLX)

Now 21% undervalued

Hologic, Inc., Annual General Meeting, Mar 07, 2024

Namal Nawana Announces Not to Stand for Re-Election to the Board of Hologic, Inc

Now 21% undervalued

Hologic, Inc. Provides Revenue Guidance for the First Quarter of 2024

Hologic, Inc. to Report Q1, 2024 Results on Feb 01, 2024

Independent Director notifies of intention to sell stock

The Price Is Right For Hologic, Inc. (NASDAQ:HOLX)

Are Investors Undervaluing Hologic, Inc. (NASDAQ:HOLX) By 25%?

Hologic, Inc. Promotes Essex D. Mitchell to Chief Operating Officer

Chairman exercised options and sold US$2.1m worth of stock

Hologic, Inc. Provides Earnings Guidance for the First Quarter and Full-Year Fiscal 2024

Full year 2023 earnings: EPS misses analyst expectations

Hologic, Inc. (NasdaqGS:HOLX) announces an Equity Buyback for $500 million worth of its shares.

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Should You Think About Buying Hologic, Inc. (NASDAQ:HOLX) Now?

Hologic, Inc. to Report Q4, 2023 Results on Nov 09, 2023

Slowing Rates Of Return At Hologic (NASDAQ:HOLX) Leave Little Room For Excitement

Nanaz Mohtashami Elected to Hologic, Inc.'S Board of Directors

Hologic, Inc.'s (NASDAQ:HOLX) Intrinsic Value Is Potentially 35% Above Its Share Price

Consensus EPS estimates fall by 22%

Hologic, Inc. Reports Impairment Charges for the Third Quarter Ended July 1, 2023

New minor risk - Earnings quality

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2023

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

Why Hologic, Inc. (NASDAQ:HOLX) Could Be Worth Watching

Hologic, Inc. to Report Q3, 2023 Results on Jul 31, 2023

Return Trends At Hologic (NASDAQ:HOLX) Aren't Appealing

Calculating The Fair Value Of Hologic, Inc. (NASDAQ:HOLX)

Hologic, Inc. Announces FDA Clearance of Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay

Insider recently sold US$200k worth of stock

Insider notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

We Think Hologic (NASDAQ:HOLX) Can Stay On Top Of Its Debt

What Does Hologic, Inc.'s (NASDAQ:HOLX) Share Price Indicate?

Hologic's (NASDAQ:HOLX) Returns On Capital Are Heading Higher

Hologic, Inc. Announces Approval of NovaSure V5 Global Endometrial Ablation Device in Canada and Europe

Calculating The Fair Value Of Hologic, Inc. (NASDAQ:HOLX)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Hologic, Inc. Provides Earnings Guidance for the Second Quarter of 2023

Hologic, Inc., Annual General Meeting, Mar 09, 2023

Hologic (NASDAQ:HOLX) Seems To Use Debt Quite Sensibly

Hologic, Inc. Revises Revenue Results for the First Quarter of Fiscal 2023

Hologic, Inc. to Report Q1, 2023 Results on Feb 01, 2023

Is Now The Time To Look At Buying Hologic, Inc. (NASDAQ:HOLX)?

Insider recently sold US$126k worth of stock

Hologic, Inc. Appoints Stacey D. Stewart to the Board of Directors, Effective January 2, 2023

Hologic, Inc. and Biotheranostics, Inc. Announce New Data Present At SABCS 2022

Chairman recently sold US$2.5m worth of stock

Shareholders Would Enjoy A Repeat Of Hologic's (NASDAQ:HOLX) Recent Growth In Returns